No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury

Faulkner, Lee, Meng, Xiaoli ORCID: 0000-0002-7774-2075, Naisbitt, Dean J, Spraggs, Colin F and Park, B Kevin ORCID: 0000-0001-8384-824X (2016) No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury. CHEMICAL RESEARCH IN TOXICOLOGY, 29 (12). pp. 2111-2113. ISSN 0893-228X, 1520-5010

	Text faulkner et al text.docx - Author Accepted Manuscript Download (94kB)
	Text fig1.pdf - Author Accepted Manuscript Download (130kB)
	Text fig2.pdf - Author Accepted Manuscript Download (84kB)
	Text fig3.pdf - Author Accepted Manuscript Download (86kB)
	Text fig4.pdf - Author Accepted Manuscript Download (83kB)
	Text fig5.pdf - Author Accepted Manuscript Download (84kB)
	Text fig6.pdf - Author Accepted Manuscript Download (85kB)

Official URL: https://doi.org/10.1021/acs.chemrestox.6b00400

Abstract

It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells. However, analysis of PBMC and cloned T-cells from patients with HLA-DRB1*07:01-restricted lapatinib-induced liver injury revealed no evidence for drug-specific activation. T cells were exposed to lapatinib, the M11 aldehyde, and quinone imine [oxidized form of hydroquinone amine M1] metabolites. Reactivity of the quinone imine was confirmed by mass spectrometry.

Item Type:	Article
Uncontrolled Keywords:	T-Lymphocytes, Humans, Quinazolines, Antineoplastic Agents, Lymphocyte Activation, HLA-DRB1 Chains, Chemical and Drug Induced Liver Injury, Lapatinib
Depositing User:	Symplectic Admin
Date Deposited:	30 Jan 2017 11:06
Last Modified:	07 Dec 2024 06:31
DOI:	10.1021/acs.chemrestox.6b00400
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3005436